Table 2.
T-cell reactivity, SARS-CoV-2 S-IgG levels, and sVNT values of IBD patients and healthy controls 6 months after the second vaccination. Partitioning of the IBD patient population was done based on immunosuppressive therapy: vedolizumab, Anti-TNF (adalimumab, infliximab), Anti-TNF + azathioprine. IBD: inflammatory bowel disease; IQR: interquartile range; p-value 1: Mann–Whitney U test (Wilcoxon); p-value 2: Kruskal–Wallis.
| T-Cell-Reactivity | IBD Patients (n = 15) |
Controls (n = 8) | p-Value 1 | Vedolizumab (n = 4) |
Anti-TNF (n = 11) |
Anti-TNF + Azathioprine (n = 0) |
p-Value 2 |
|---|---|---|---|---|---|---|---|
| Positive T-Cell reactivity (%) | 11 (73) | 6 (67) | 0.189 | 3 (75) | 8 (73) | 0 (0) | 1.000 |
| Marginal T-Cell reactivity (%) | 4 (27) | 1 (13) | 0.189 | 1 (25) | 3 (27) | 0 (0) | 1.000 |
| Negative T-Cell reactivity (%) | 0 (0) | 1 (13) | 0.189 | 0 (0) | 0 (0) | 0 (0) | 1.000 |
| Humoral Reactivity |
IBD Patients
(n = 20) |
Controls (n = 8) | p-Value 1 |
Vedolizumab
(n = 4) |
Anti-TNF
(n = 14) |
Anti-TNF + Azathioprine
(n = 2) |
p-Value 2 |
| SARS-CoV-2 S-IgG (AU/mL), median (IQR) | 189 (22–514) | 1018 (618–1583) | 0.001 | 694 (370–3633) | 141 (0–340) | 98 | 0.057 |
| Seroconversion rate S-IgG (%) | 75 | 100 | 0.153 | 100 | 64 | 100 | 0.640 |
| sVNT (%), median (IQR) | 14 (0–52) | 79 (57–85) | 0.002 | 55 (31–87) | 2 (0–42) | 0 | 0.042 |
| Seroconversion rate sVNT (%) | 45 | 100 | 0.005 | 75 | 43 | 0 | 0.088 |